Disease-Modifying Therapies for Multiple Sclerosis

Disease-modifying therapies (DMTs) represent the core pharmacological strategy for altering the long-term course of multiple sclerosis, distinct from treatments that address acute relapses or manage symptoms. This page covers how DMTs are classified, the biological mechanisms through which they act, the clinical contexts in which they are deployed, and the decision criteria that guide therapy selection. Understanding this class of agents is essential for anyone navigating the treatment landscape for multiple sclerosis as a chronic neurological condition.

Definition and scope

A disease-modifying therapy for multiple sclerosis is any agent that reduces the frequency of clinical relapses, slows the accumulation of disability, or limits new lesion formation on MRI — as opposed to treating symptoms or recovering function after an attack. The U.S. Food and Drug Administration (FDA) has approved more than 20 distinct DMTs for MS as of the mid-2020s, spanning oral, injectable, and intravenous formulations (FDA Drug Approvals and Databases).

DMTs are approved for specific MS phenotypes. The FDA distinguishes approvals across:

  1. Relapsing-remitting MS (RRMS) — the most common form, characterized by discrete attacks followed by partial or full recovery
  2. Secondary progressive MS (SPMS) with active disease — progression with ongoing relapses or new MRI activity
  3. Primary progressive MS (PPMS) — a continuously worsening course without distinct relapses
  4. Clinically isolated syndrome (CIS) — a first demyelinating episode that may or may not convert to MS

Ocrelizumab (Ocrevus) holds the distinction of being the first FDA-approved DMT for PPMS, receiving approval in 2017. The regulatory context for neurological conditions in the United States means that each approval carries a specific labeled indication, and off-label use introduces distinct clinical and legal considerations.

How it works

DMTs act through immunomodulatory or immunosuppressive mechanisms, targeting the aberrant immune activity that drives demyelination and axonal injury in MS. The mechanisms differ substantially across drug classes:

The National Multiple Sclerosis Society (NMSS) organizes DMTs into efficacy tiers — moderate-efficacy and high-efficacy — a framework widely referenced in clinical practice guidelines (NMSS Disease Management Consensus Statement).

Common scenarios

DMT initiation is most common at the point of a confirmed relapsing MS diagnosis, guided by the 2017 McDonald Criteria revised by the International Panel on Diagnosis of MS. Three broad clinical scenarios shape prescribing patterns:

Newly diagnosed RRMS with low-to-moderate lesion burden: Moderate-efficacy agents such as dimethyl fumarate, teriflunomide, or glatiramer acetate are frequently used as first-line options. These carry more established long-term safety profiles relative to high-efficacy agents.

Newly diagnosed RRMS with high lesion burden or rapid relapse history: An "early high-efficacy" strategy, supported by observational data from the MSBase registry, favors initiating natalizumab, anti-CD20 agents, or alemtuzumab at diagnosis rather than after first-line failure. Research published in JAMA Neurology has examined disability outcomes under escalation versus early high-efficacy strategies, though head-to-head randomized data remain limited.

Breakthrough disease on existing therapy: When a patient experiences relapses or new MRI lesions despite adherence to a current DMT, treatment escalation is indicated. The risk-benefit calculus shifts toward accepting higher safety monitoring burdens in exchange for greater efficacy.

Patients interested in the broader context of living with this condition can find relevant information at living with multiple sclerosis.

Decision boundaries

Therapy selection is constrained by five primary decision boundaries:

  1. MS phenotype and FDA-labeled indication — No DMT carries a label for all MS subtypes; prescribing outside the labeled indication requires documented clinical rationale.
  2. JC virus antibody status — Natalizumab carries a Black Box Warning for PML. JC antibody index stratifies risk; an index above 1.5 in JC-antibody-positive patients corresponds to substantially elevated PML risk per the FDA prescribing information (Tysabri Prescribing Information, FDA).
  3. Pregnancy and reproductive planning — Teriflunomide is teratogenic and requires accelerated elimination procedures before conception. Natalizumab, cladribine, and alemtuzumab each carry reproductive safety restrictions detailed in FDA Risk Evaluation and Mitigation Strategies (REMS) programs.
  4. Cardiac and pulmonary status — S1P receptor modulators require first-dose cardiac monitoring for patients with pre-existing arrhythmias or conduction abnormalities, per FDA labeling.
  5. Comorbid immunosuppression — Concurrent immunosuppressive agents elevate infection risk across all high-efficacy DMTs, necessitating infectious disease screening (hepatitis B, hepatitis C, tuberculosis, varicella-zoster status) before initiation.

The FDA's MedWatch program and REMS database serve as the authoritative registries for ongoing safety obligations attached to specific DMTs (FDA REMS Database).

High-efficacy DMTs and moderate-efficacy DMTs are not interchangeable along a single risk axis. Moderate-efficacy agents generally have longer post-market safety records but lower relapse reduction rates — approximately 29–53% versus 50–68% or higher for high-efficacy agents — while high-efficacy agents require more intensive laboratory and clinical monitoring. Matching therapy intensity to disease activity remains the central challenge in MS disease management, governed by evolving national and international clinical practice guidelines from organizations including the American Academy of Neurology (AAN) (AAN Clinical Practice Guidelines).

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)